Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
